Total Price: $0.00
Contact Information
Recombinant Human VEGFR3/FLT4 Protein (His Tag)(Active)
SKU: PKSH031419-100
Recombinant Human VEGFR3/FLT4 Protein (His Tag)(Active)
| SKU # | PKSH031419 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | FLT-4, FLT-41, FLT41, LMPH1A, PCL, VEGF Receptor 3, VEGFR-3, VEGFR3 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Ile 776 |
| Accession | NP_002011.2 |
| Calculated Molecular Weight | 86.0 kDa |
| Observed Molecular Weight | 130 kDa |
| Tag | C-His |
| Bio-activity | Measured by its binding ability in a functional ELISA. Immobilized human VEGF-C at 10 μg/mL (100 μl/well) can bind human VEGFR3-his. The EC50 of human VEGFR3-his is 0.011 μg/mL. Measured by its ability to bind human VEGF-D in a functional ELISA. |
Properties
| Purity | > 97 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.